Clinical Trial

Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

Name: Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma — clinical trial record (NCT07615283)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

To evaluate the safety of adebrelimab combined with SHR2554 in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTCL), to determine the recommended Phase 2 dose (RP2D) of the combination regimen, and to assess preliminary efficacy.

Trial Details

NCT Number	NCT07615283
Lead Sponsor	Sun Yat-sen University
Conditions	Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL
Enrollment	40 participants
Start Date	2026-05-29
Primary Completion	2030-05-29 (estimated)
Study Completion	2030-10-29 (estimated)
Updated on ClinicalTrials.gov	2026-05-29